Carna Biosciences enters collaboration with Janssen Biotech

15 June 2015
2019_biotech_test_vial_discovery_big

Japan-based Carna Biosciences (TYO: 4572) has signed a worldwide licensing agreement with Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), to further develop and commercialize compounds from one of Carna’s small-molecule protein kinase inhibitor programs.

Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, California and Asia Pacific, Carna Biosciences, a 2003 spinoff of Japan Organon, will receive an initial upfront payment and is eligible to receive additional milestone payments upon achievement of certain developmental, regulatory, and commercial milestones. Carna Biosciences will also be eligible to receive tiered royalties on the net sales of commercialized licensed products.

“We are pleased to collaborate with Janssen to further develop one of our kinase inhibitor programs. Our hope is that our discovery efforts will someday make a meaningful difference in the lives of people living with immunologic disease,” said Kohichiro Yoshino, founder, president and chief executive of Carna Biosciences. “This agreement with Janssen is an important first step towards the goal of discovering and developing significant therapeutic solutions for improving human health. Carna Biosciences will continue to identify and develop innovative compounds with strong potential as therapeutic kinase inhibitors,” Dr Yoshino added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology